A -- Evaluation of Chemopreventive Agents by In Vitro Screening Assays

The National Cancer Institute (NCI), Division of Cancer Prevention (DCP), Chemoprevention Agent Development Group (CADRG), is interested in evaluating inhibitors of carcinogenesis in vitro, in order to identify potential chemopreventive agents against cancer. Such agents would be further evaluated in appropriate animal efficacy or clinical settings. The CADRG has established a clearly defined integrated plan for the evaluation of chemopreventive agents. This plan delineates criteria for classifying information that currently exists on any chemopreventive agent and thus defines what additional information and investigations are required to qualify the agent's experimental use in intervention trials of human cancer. The primary purpose of this RFP is to use in vitro methods to screen chemopreventive agents (see Methods in Cell Biology Vol 19(1):1-70, 1997). The objective of these studies is to determine the efficacy of chemopreventive agents in an array of in vitro model systems representing different cell substrates, those of human origin in particular. The studies are designed to rank-order and prioritize agents for further development. Those interested in obtaining a copy of this RFP should send their e-mail address to Dorothy McMillan at dm308v@nih.gov and a copy of the RFP will be forwarded electronically. AN AWARD WILL ONLY BE MADE TO A MASTER AGREEMENT HOLDER IN THE IN VITRO MASTER AGREEMENT POOL. The North American Industry Classification System (NAICS) code is 54171. Those who are not currently in the In Vitro Master Agreement Pool and who wish to be considered for inclusion should consult the Research Contracts Branch web site at Http://amb.nci.nih.gov under "Current Requests for Proposals" and refer to RFP/N01-CN-85093-40. It is anticipated that the RFP will be available around the middle of April 2002. Questions should be directed, via facsimile or e-mail, to Dorothy McMillan, Contract Specialist, Prevention and Control Contracts Section, Research Contracts Branch, National Cancer Institute, Bethesda, MD 20892-7226. Phone: (301) 435-3828; fax: (301) 402-8579; e-mail: dm308v@nih.gov. Please NOTE: As result of move to temporary location, a corrected address for contracting office will be forwarded to interested parties prior to RFP deadline. NO COLLECT CALLS WILL BE ACCEPTED. Numbered Note 26: Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the contracting officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice.